Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 295

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 1A
Chunk 295
---
 commercialization milestones under our collaborations; 

•failure or discontinuation of any of our product development and research programs; 

•results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; 

•the level of expenses related to any of our research programs, clinical development programs or product candidates that we may develop; 

•the results of our efforts to develop additional product candidates or products; 

•regulatory actions with respect to our products or those of our competitors; 

•developments or disputes concerning patent applications, issued patents or other proprietary rights; 

•announced or completed acquisitions of businesses, products or intellectual property by us or our competitors; 

•actual or anticipated changes in the financial projections or development timelines we may provide to the public or our failure to meet those projections or timelines; 

•market conditions in the biotechnology, pharmaceutical and ophthalmology sectors; 

•changes in the structure of healthcare payment systems;

•sales of shares of our common stock by us or our stockholders, or expectations that such sales may occur, and the expiration of market stand-off or lock-up agreements; 

•the recruitment or departure of key personnel; 

•the public’s reaction to our press releases, other public announcements, and filings with the SEC; 

•rumors and market speculation involving us or other companies in our industry; 

•fluctuations in the trading volume of our shares or the size of our public float; 

•actual or anticipated changes or fluctuations in our results of operations; 

79

Table of Contents

•actual or anticipated developments in our business, our competitors’ businesses, or changes in the market valuations of similar companies and the competitive landscape generally; 

•changes in the market valuations of similar companies; 

•failure of securities analysts to maintain coverage of us, changes in actual or future expectations of investors or securities analysts, or our failure to meet these estimates or the expectations of investors;

•litigation involving us, our industry or both; 

•governmental or regulatory actions or audits; 

•regulatory or legal developments in the United States and other countries; 

•general economic conditions and trends; 

•announcement or expectation of additional financing efforts; 

•sales of securities by us or our security holders in the future; and

•changes in accounting standards, policies, guidelines, interpretations, or principles.

Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating